Skip to Content
Merck
CN
  • SOX2 is a cancer-specific regulator of tumour initiating potential in cutaneous squamous cell carcinoma.

SOX2 is a cancer-specific regulator of tumour initiating potential in cutaneous squamous cell carcinoma.

Nature communications (2014-08-01)
Jasmin M Siegle, Alice Basin, Ana Sastre-Perona, Yoshiya Yonekubo, Jessie Brown, Rachel Sennett, Michael Rendl, Aristotelis Tsirigos, John A Carucci, Markus Schober
ABSTRACT

Although the principles that balance stem cell self-renewal and differentiation in normal tissue homeostasis are beginning to emerge, it is still unclear whether cancer cells with tumour initiating potential are similarly governed, or whether they have acquired distinct mechanisms to sustain self-renewal and long-term tumour growth. Here we show that the transcription factor Sox2, which is not expressed in normal skin epithelium and is dispensable for epidermal homeostasis, marks tumour initiating cells (TICs) in cutaneous squamous cell carcinomas (SCCs). We demonstrate that Sox2 is required for SCC growth in mouse and human, where it enhances Nrp1/Vegf signalling to promote the expansion of TICs along the tumour-stroma interface. Our findings suggest that distinct transcriptional programmes govern self-renewal and long-term growth of TICs and normal skin epithelial stem and progenitor cells. These programmes present promising diagnostic markers and targets for cancer-specific therapies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
ChIPAb+ Sox-2, clone 6F1.2 - ChIP Validated Antibody and Primer Set, clone 6F1.2, from mouse
Roche
cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail, Tablets provided in EASYpacks